Related Experiment Videos

Corrigendum: Drug therapy in anticoagulation: which drug for which patient?

Carolyn M Millar¹, Mike A Laffan²

¹Imperial College, London, UK and consultant haematologist, Imperial College Healthcare NHS Trust, London, UK.

Clinical Medicine (London, England)

|August 3, 2017

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results.

Research and practice in thrombosis and haemostasis·2026

TFPIα inhibition by andexanet alfa is partially restored by protein S and factor V-short.

Blood advances·2026

Anticoagulation, recurrent thrombosis, and major bleeding in antiphospholipid syndrome: UK multicenter observational study.

Blood advances·2026

Von Willebrand factor deficiency impairs angiogenesis via angiopoietin-2: relevance for gut angiodysplasia.

Blood·2026

Enhancing hemostasis potency in hemophilia with a small interfering ribonucleic acid targeting protein S.

Journal of thrombosis and haemostasis : JTH·2025

Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial.

Research and practice in thrombosis and haemostasis·2024

See all related articles